Anatara Lifesciences (ASX:ANR) has provided an update on the recruitment progress for Stage 2 of its pivotal GaRP-IBS - irritable bowel syndrome - trial.
The company said its focus has been on completing the recruitment for Stage 2 in the current quarter of the calendar year 2024. it said the minimum target participant number for Stage 2 is 60.
Anatara's GaRP product is a multi-component, multi-coated complementary medicine designed to address underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD.
Anatara executive chair Dr David Brookes said, “Progress has continued at a satisfactory rate and the company is extremely pleased to progress towards and beyond the minimum number of 60 participants sought for Stage 2. We intend to pause recruitment at the end of next week and will decide about any need for resumption early in the New Year. This only leaves a short window of days for any new participants to be involved in the screening process.
"I really encourage any IBS sufferers considering involvement, and who meet the criteria sub-types of IBS-Diarrhoeal predominant or IBSMixed pattern, to submit their expression of interest within the next few days otherwise any opportunity for recruitment may have lapsed. It is simply a matter of going to the Anatara website or by using ibstrial.au to find the link to the clinic in their geographical zone to register an interest. From there, the next step is an online questionnaire before deciding on consent and a clinic visit.
"The trial of our GaRP product as potentially an emerging treatment for a difficult medical condition is a significant commitment and we appreciate the contribution of the participants to selflessly consider and comply with the trial conditions. On behalf of the Company, the investigators and staff of the trial sites, I again take the opportunity to thank all those who have expressed interest to be involved including those that did not meet the criteria to be enrolled.”
